EXEL 伊克力西斯

添加自选

23.460
-0.270-1.14%

收盘价 04/30 16:00 (美东)

21.750
-1.710-7.29%

盘后 19:11 (美东)

69.16亿总市值36.09市盈率TTM

关于伊克力西斯公司

Exelixis 是一家发现、开发和商业化癌症治疗的生物制药公司，其先导分子 cabozantinib 以 Cometriq 为名用于治疗转移性甲状腺髓样癌患者，以 Cabometyx 为名用于治疗肾癌和肝癌。 Exelixis 及其合作伙伴罗氏也将 Cotellic 推向了治疗黑色素瘤的市场。

公司介绍

公司代码EXEL

公司名称伊克力西斯

上市日期2000/04/11

发行价格13.00

成立日期1994

CEODr. Michael M. Morrissey, PhD

所属市场纳斯达克

员工数量1310

证券类型海外普通股

年结日12-29

公司地址1851 Harbor Bay Parkway

城市Alameda

省份加利福尼亚州

国家美国

邮编94502

电话1-650-837-7000

网址http://www.exelixis.com

董事高管

姓名
职务
年薪

Dr. Michael M. Morrissey, PhD
Director, President and Chief Executive Officer
1642.33万

Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
736.78万

Christopher J. Senner
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
494.76万

Dr. Dana T. Aftab, PhD
Chief Scientific Officer and Executive Vice President, Discovery and Translational Research
565.31万

Jeffrey J. Hessekiel
Executive Vice President, General Counsel and Secretary
456.27万

Patrick J. Haley
Executive Vice President, Commercial
156.47万

Dr. Stelios Papadopoulos,PhD
Chairman of the Board
52.00万

Dr. Sue Gail Eckhardt, M.D.
Director
--

Dr. Mary C. Beckerle, PhD
Director
--

Dr. Alan M. Garber, M.D.,PhD
Independent Director
48.12万

Tomas J. Heyman
Independent Director
71.62万

Dr. George H. Poste, D.V.M.,F.R.S.,PhD
Independent Director
43.11万

Robert Oliver, M.B.A.
Independent Director
71.74万

Jack L. Wyszomierski, M.S.
Independent Director
49.10万

Dr. Maria C. Freire, PhD
Independent Director
48.87万

Jacqueline Wright
Independent Director
47.15万

Julie Anne Smith
Independent Director
49.09万

David E. Johnson
Independent Director
71.87万

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度